Immune checkpoint inhibitors in patients with lung cancer having chronic interstitial pneumonia.
Kazutoshi IsobeYasuhiko NakamuraSusumu SakamotoKeisuke TomiiTakayuki TakimotoYasunari MiyazakiMasaru MatsumotoKeishi SuginoKazuya IchikadoShuhei MoriguchiKakuhiro YamaguchiTomohisa BabaHiroaki OzasaFumiyasu IgataKazuki AnabukiSakae HommaHiroshi DateTakafumi SudaKazuma KishiPublished in: ERJ open research (2024)
Although ICI treatment was effective for patients with lung cancer with IP, ICIP developed in approximately 30% of patients. Patients with irAEs had a significantly better PFS and OS than those without irAEs.